PT  - JOURNAL ARTICLE
AU  - Liu, Ya-Fei
AU  - Zhang, Zhe
AU  - Pan, Xiao-Li
AU  - Xing, Guo-Lan
AU  - Zhang, Ying
AU  - Liu, Zhang-Suo
AU  - Tu, Sheng-Hao
TI  - The Chronic Kidney Disease and Acute Kidney Injury Involvement in COVID-19 Pandemic: A Systematic Review and Meta-analysis
AID  - 10.1101/2020.04.28.20083113
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.28.20083113
4099  - http://medrxiv.org/content/early/2020/05/02/2020.04.28.20083113.short
4100  - http://medrxiv.org/content/early/2020/05/02/2020.04.28.20083113.full
AB  - Aim The aim of this study was to uncover whether kidney diseases were involved in COVID-19 pandemic from a systematic review.Methods The studies reported the kidney outcomes in different severity of COVID-19 were included in this study. Standardized mean differences or odds ratios were calculated by employing Review Manager meta-analysis software.Results Thirty-six trials were included in this systematic review with a total of 6395 COVID-19 patients. The overall effects indicated that the comorbidity of chronic kidney disease (CKD) (OR = 3.28), complication of acute kidney injury (AKI) (OR = 11.02), serum creatinine (SMD = 0.68), abnormal serum creatinine (OR = 4.86), blood urea nitrogen (SMD = 1.95), abnormal blood urea nitrogen (OR = 6.53), received continuous renal replacement therapy (CRRT) (OR = 23.63) was significantly increased in severe group than that in nonsevere group. Additionally, the complication of AKI (OR = 13.92) and blood urea nitrogen (SMD = 1.18) were remarkably elevated in critical group than that in severe group.Conclusion CKD and AKI are susceptible to occur in patients with severe COVID-19. CRRT is applied frequently in severe COVID-19 patients than that in nonsevere COVID-19 patients. The risk of AKI is higher in critical group than that in severe group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the National Natural Science Foundation of China (81701601).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request.